c-kit mutation for exon 11

This topic has 9 replies, 3 voices, and was last updated 13 years, 6 months ago by JerryfromFauq.

Post

- November 12, 2011 at 2:00 pm
- Quote
beccia1
Participant
the genetic testing indicated that i have the c-kit mutation for exon 11

i was wondewring what tuype of drug is prescribed for that mutation

john b

the genetic testing indicated that i have the c-kit mutation for exon 11

i was wondewring what tuype of drug is prescribed for that mutation

john b

Viewing 8 reply threads

Replies

- November 12, 2011 at 3:18 pm
- Quote
sharmon
Participant
Hi, You might want to look in Gleevac. Hope this helps.
- November 12, 2011 at 3:18 pm
- Quote
sharmon
Participant
Hi, You might want to look in Gleevac. Hope this helps.
- November 12, 2011 at 3:18 pm
- Quote
sharmon
Participant
Hi, You might want to look in Gleevac. Hope this helps.

November 12, 2011 at 9:42 pm

Quote

LynnLuc

Participant

KIT mutations are usually found in tumors wildtype for NRAS, BRAF

Specifically imatinib holds promise -here are 5 trials using it

Phase II Study of Imatinib Mesylate in Patients With Inoperable Stage III or IV Melanoma and Somatic Alterations of c-KIT

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-07014, 7754, 07-014, NCT00470470

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-244, DUS11T, NCT00788775

Reduced Intensity Transplant Using Extracorporeal Photopheresis

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790

Study of Nilotinib in Metastatic Melanoma With KIT Aberrations

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-02-026, NCT01099514

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2005-003, EudraCT:2006-002015-27, NCT00623831

November 12, 2011 at 9:42 pm

Quote

LynnLuc

Participant

KIT mutations are usually found in tumors wildtype for NRAS, BRAF

Specifically imatinib holds promise -here are 5 trials using it

Phase II Study of Imatinib Mesylate in Patients With Inoperable Stage III or IV Melanoma and Somatic Alterations of c-KIT

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-07014, 7754, 07-014, NCT00470470

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-244, DUS11T, NCT00788775

Reduced Intensity Transplant Using Extracorporeal Photopheresis

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790

Study of Nilotinib in Metastatic Melanoma With KIT Aberrations

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-02-026, NCT01099514

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2005-003, EudraCT:2006-002015-27, NCT00623831

November 12, 2011 at 9:42 pm

Quote

LynnLuc

Participant

KIT mutations are usually found in tumors wildtype for NRAS, BRAF

Specifically imatinib holds promise -here are 5 trials using it

Phase II Study of Imatinib Mesylate in Patients With Inoperable Stage III or IV Melanoma and Somatic Alterations of c-KIT

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-07014, 7754, 07-014, NCT00470470

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-244, DUS11T, NCT00788775

Reduced Intensity Transplant Using Extracorporeal Photopheresis

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790

Study of Nilotinib in Metastatic Melanoma With KIT Aberrations

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-02-026, NCT01099514

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2005-003, EudraCT:2006-002015-27, NCT00623831

- November 13, 2011 at 7:57 am
- Quote
JerryfromFauq
Participant
There are several trials currently in progress to determine which of the C-kit drugs works best on which Exon mutation. All reports that I have found so far state that Gleevec has shown the best results for exon 11 DNA mutations.

I have been essentially stable on Gleevec since March 2009. My melanoma had been going wild for the three months before that.

I would be happy to discuss my c-kit experiences with you. Let me know what you would like. We can email, chat or talk telephonically.

[email protected]
- November 13, 2011 at 7:57 am
- Quote
JerryfromFauq
Participant
There are several trials currently in progress to determine which of the C-kit drugs works best on which Exon mutation. All reports that I have found so far state that Gleevec has shown the best results for exon 11 DNA mutations.

I have been essentially stable on Gleevec since March 2009. My melanoma had been going wild for the three months before that.

I would be happy to discuss my c-kit experiences with you. Let me know what you would like. We can email, chat or talk telephonically.

[email protected]
- November 13, 2011 at 7:57 am
- Quote
JerryfromFauq
Participant
There are several trials currently in progress to determine which of the C-kit drugs works best on which Exon mutation. All reports that I have found so far state that Gleevec has shown the best results for exon 11 DNA mutations.

I have been essentially stable on Gleevec since March 2009. My melanoma had been going wild for the three months before that.

I would be happy to discuss my c-kit experiences with you. Let me know what you would like. We can email, chat or talk telephonically.

[email protected]

Viewing 8 reply threads

You must be logged in to reply to this topic.

About the MRF Patient Forum

Popular Topics

c-kit mutation for exon 11

About the MRF Patient Forum

Popular Topics

Topic Tags